Enveric Biosciences
ENVB
11 hedge funds and large institutions have $107K invested in Enveric Biosciences in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
21% more capital invested
Capital invested by funds: $87.7K → $107K (+$18.9K)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.09% less ownership
Funds ownership: 4.05% → 3.95% (-0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$87.7K |
| 2 |
Jones Financial Companies
Des Peres,
Missouri
|
+$2.73K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.96K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
+$93 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$8.26K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.22K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$18 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $62.4K | +$87.7K | +32,149 | New |
|
|
AI
2
AdvisorShares Investments
Bethesda,
Maryland
| $32.9K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $7.01K | +$1.96K | +717 | +25% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $2.14K | -$2.22K | -814 | -42% |
|
|
5
Jones Financial Companies
Des Peres,
Missouri
| $1.88K | +$2.73K | +1,000 | New |
|
|
SS
6
SBI Securities
Tokyo,
Japan
| $161 | +$93 | +34 | +69% |
|
7
BlackRock
New York
| $99 | – | – | – |
|
|
DB
8
Danske Bank
Copenhagen K,
Denmark
| $2 | – | – | – |
|
9
Group One Trading
Chicago,
Illinois
| $2 | – | – | – |
|
10
National Bank of Canada
Montreal,
Quebec, Canada
| $2 | – | – | – |
|
11
Wells Fargo
San Francisco,
California
| $2 | – | – | – |
|
|
12
Citigroup
New York
| – | -$8.26K | -2,276 | Closed |
|
|
13
Bank of America
Charlotte,
North Carolina
| – | -$18 | -5 | Closed |
|
ENVB Hedge Fund Activity: Q1 2026 in Review
11 of the 8,133 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q1 2026, worth a combined $107K — up 21% from $87.7K a quarter earlier.
Fund positioning in ENVB was balanced in Q1 2026: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $87.7K. The largest seller was Citigroup, exiting entirely with an estimated $8.26K sold.
- 11 institutional investors held Enveric Biosciences (ENVB) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $107K of Enveric Biosciences stock for Q1 2026, up 21% quarter-over-quarter.
- 2 funds opened new Enveric Biosciences positions in Q1 2026 and 2 closed out, a net change of 0 holders.
- The largest Enveric Biosciences buyer in Q1 2026 was Geode Capital Management, an estimated $87.7K added.
- The largest Enveric Biosciences seller in Q1 2026 was Citigroup, an estimated $8.26K sold.
Based on aggregated 13F filings for Q1 2026.